A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease

British Journal of Clinical Pharmacology

Volumn 75, Issue 5, 2013, Pages 1231-1239

  Moss, Donald E ^a   Fariello, Ruggero G ^b   Sahlmann, Jörg ^c,e   Sumaya, Isabel ^a,f   Pericle, Federica ^d   Braglia, Enrico ^d  

^a UNIVERSITY OF TEXAS AT EL PASO   (United States)

^b BioNeuroFar SA   (Switzerland)

^c Scope International GmbH   (Germany)

^d Senexta Therapeutics SA   (Switzerland)

^e MPS Hamburg GmbH   (Germany)

^f CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Cholinesterase inhibition; Methanesulfonyl fluoride; MSF; Phase I human study

Indexed keywords

ACETYLCHOLINESTERASE; AMYLASE; METHANESULFONYL FLUORIDE; PLACEBO; SNX 001; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMAL DREAMING; AGED; AGITATION; ALZHEIMER DISEASE; AMYLASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; COHORT ANALYSIS; CONFUSION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; ENZYME INHIBITION; ENZYME KINETICS; ERYSIPELAS; FEMALE; FLATULENCE; HEART PALPITATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYPERHIDROSIS; HYPERTENSION; LIMB PAIN; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NAUSEA; NIGHTMARE; NONHUMAN; NORMAL HUMAN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; REPEATED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ACETYLCHOLINESTERASE; AGED; ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ERYTHROCYTE MEMBRANE; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; RATS; RATS, SPRAGUE-DAWLEY; SULFONES;

EID: 84876046612     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12018     Document Type: Article

References (18)

1. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-414.
2. Whitehouse PB, Price DL, Struble RG, Clark AW, Coyle JT, Delong MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215: 1237-1239.
3. Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 2001; 15: 375-390.
4. Nordgren I. Cholinesterase inhibitors - are they all the same? Int J Ger Psychopharmacol 1998; 1: 176-178.
5. Moss DE, Kobayashi H, Pacheco G, Palacios R, Perez RG. Methanesulfonyl fluoride: a CNS selective cholinesterase inhibitor. In: Current Research in Alzheimer Therapy: Cholinesterase Inhibitors, eds Giacobini E, Becker R New York: Taylor and Francis, 1988; 305-314.
6. Kobayashi H, Nakano T, Moss DE, Tadahiko S. Effects of a central anticholinesterase, methanesulfonyl fluoride on the cerebral cholinergic system and behavior in mice: comparison with an organophosphate DDVP. J Health Sci 1999; 45: 191-202.
7. Lotti M, Moretto A. Organophosphate-induced delayed polyneuropathy. Toxicol Rev 2005; 24: 37-49.
8. Marquis JK. Contemporary Issues in Pesticide Toxicology and Pharmacology (Concepts in Toxicology, Vol. 2). Basel, New York: Karger, 1986.
9. Caroldi S, Lotti M, Masutti A. Intra-arterial injection of DFP or PMSF produces unilateral neuropathy or protection, respectively, in hens. Biochem Pharmacol 1984; 33: 3213-3217.
10. Osman KA, Moretto A, Lotti M. Sulfonyl fluorides and the promotion of diisopropyl flurophosphate neuropathy. Fundam Appl Toxicol 1996; 33: 294-297.
11. Moss DE, Berlanga P, Hagan MM, Sandoval H, Ishida C. Methanesulfonyl fluoride (MSF): a double blind, placebo controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 1999; 13: 20-25.
12. Ellman GL, Courtney KD, Andres V Jr, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 85-95.
13. Snow AW, Barger WR. A chemical comparison of methanesulfonyl fluoride with organofluorophosphorus ester anticholinesterase compounds. Chem Res Toxicol 1988; 1: 379-384.
14. Unni L, Vicari S, Moriearty P, Schaefer F, Becker R. The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer's disease patients after treatment with metrifonate. Methods Find Exp Clin Pharmacol 2000; 22: 57-61.
15. Malin DH, Plotner RE, Radulescu SJ, Ferebee RN, Lake JR, Negrete PG, Schaefer PJ, Crothers MK, Moss DE. Chronic methanesulfonyl fluoride enhances one-trial per day reward in aged rats. Neurobiol Aging 1993; 14: 393-395.
16. Tallarida RJ, Murray RB. Manual of Pharmacologic Calculations with Computer Programs. New York: Springer-Verlag, 1986.
17. Imanishi T, Hossain MM, Suzuki T, Xu P, Itaru S, Kobayashi H. Effect of a CNS-sensitive anticholinesterase methane sulfonyl fluoride on hippocampal acetylcholine release in freely moving rats. Adv Pharm Sci 2012; 2012 (Article ID708178). DOI: 10.1155/2012/708178.
18. Borlongan CV, Sumaya I, Moss DE. Methanesulfonyl fluoride, an acetylcholinesterase inhibitor, attenuates cognitive deficits in ischemic rats. Brain Res 2005; 1038: 50-58.